Niranjan Awasthi

5PUBLICATIONS
7CO-AUTHORS
ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 03, 2024
Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models.

Niranjan Awasthi, Lily Darman, Margaret A Schwarz

|May 02, 2022
Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy.

Niranjan Awasthi, Margaret A Schwarz, Changhua Zhang

|Dec 09, 2021
Targeted FGFR/VEGFR/PDGFR inhibition with dovitinib enhances the effects of nab-paclitaxel in preclinical gastric cancer models.

Kate Crawford, Erin Bontrager, Margaret A Schwarz

|May 03, 2021
Targeted dual inhibition of c-Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models.

Meghan Grojean, Margaret A Schwarz, Johann R Schwarz

|Apr 04, 2019
Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer.

Niranjan Awasthi, Amanda J Mikels-Vigdal, Erin Stefanutti

Pageof 1

Frequent Collaborators

2 joint publications

Roderich E Schwarz

1 joint publications

Margaret A Schwarz

1 joint publications

Changhua Zhang

1 joint publications

Stephan G Klinz